· Published by Health Canada · Official notice
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
April 27, 2005
Subject: Association of TRILEPTAL (oxcarbazepine) with life-threatening dermatological reactions and multi-organ hypersensitivity
Dear Health Care Professional,
Novartis Pharmaceuticals Canada Inc., following discussion with Health Canada, would like to inform you about new safety information concerning the risk of serious dermatological reactions, including Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), as well as multi-organ hypersensitivity reactions in both children and adults, associated with the use of TRILEPTAL (oxcarbazepine).
The WARNINGS AND PRECAUTIONS section of the TRILEPTAL Product Monograph is being revised as appropriate. Please carefully review the information noted below:
Life-threatening Dermatological Reactions
Multi-Organ Hypersensitivity
Cross-Sensitivity with Carbamazapine
TRILEPTAL is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children ages 6-16 with epilepsy.
The Consumer Information section of the TRILEPTAL Product Monograph is being updated accordingly.
The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of serious and/or unexpected adverse reactions in patients receiving TRILEPTAL should be reported to Novartis Pharmaceuticals Canada Inc. or Health Canada.
Novartis is committed to the safety and well being of all patients receiving TRILEPTAL (oxcarbazepine) tablets and oral suspension. If you become aware of any case(s) of the events described above, in patients treated with TRILEPTAL, please report the event promptly to:
Novartis Pharmaceuticals Canada Inc.
385 Bouchard blvd,
Dorval, (QC) H9S 1A9
Phone:1-800-363-8883 (Medical Information)
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
Email: cadrmp@hc-sc.gc.ca
For other inquiries, please refer to contact information:
Bureau of Cardiology, Allergy and Neurological Sciences (BCANS)
BCANS_Enquiries@hc-sc.gc.ca
Tel: (613) 941-1499
Fax: (613) 941-1668
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
Should you have any questions or require additional information regarding the use of TRILEPTAL (oxcarbazepine), please contact Novartis Pharmaceuticals Canada Inc., Medical Information at 1-800-363-8883 from 8:30 AM to 4:30 PM Monday to Friday Eastern Standard Time.
Sincerely,
original signed by
Pier-Giorgio Fontana, Ph. D. Vice-President, Regulatory Affairs
Jean-Marie Leclerc, M.D., FRCP (c) Vice-President, Clinical and Regulatory Affairs.